IPO

Found 16,900 articles

• SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes

  10/2/2023

  SAB Biotherapeutics today announced the Company has entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain accredited investors (the “Investors”), pursuant to which the Company agreed to issue and sell shares of preferred stock in a private placement (the “Offering”).

• Vistagen Announces Pricing of $100 Million Underwritten Offering

  10/2/2023

  Vistagen Therapeutics, Inc. today announced the pricing of a $100 million underwritten offering of its common stock (or pre-funded warrants to purchase common stock) and warrants to purchase common stock.

• UL Solutions Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering

  10/2/2023

  UL Solutions Inc. (the “Issuer”) today announced that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission (the “SEC”) relating to a proposed secondary offering by UL Standards & Engagement, the nonprofit organization that is currently the sole stockholder of the Issuer, of Class A common stock of the Issuer.

• Adlai Nortye Ltd. Announces Pricing of Initial Public Offering - September 29, 2023

  9/29/2023

  Adlai Nortye Ltd. announced the pricing of its initial public offering of 2,500,000 American depositary shares, or 2,875,000 ADSs if the underwriters exercise their over-allotment option in full, each representing three Class A ordinary shares, at a public offering price of US$23.00 per ADS.

• SciSparc Announces Expected Implementation of 1-for-26 Reverse Share Split

  9/27/2023

  SciSparc Ltd. announces today that its previously announced reverse share split of its issued and outstanding ordinary shares.

• HARMONY BIOSCIENCES ANNOUNCES EXTENSION OF TENDER OFFER TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC.

  9/27/2023

  Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), today announced that Xylophone Acquisition Corp., a wholly owned subsidiary of Harmony, has extended the expiration of its tender offer to acquire all of the outstanding shares of common stock.

• Xeris Biopharma Announces Private Convertible Note Exchange Transactions

  9/27/2023

  Xeris Biopharma Holdings, Inc. today announced that on September 26, 2023, it and Xeris Pharmaceuticals, Inc., a wholly owned subsidiary of Xeris (the “Guarantor”), entered into separate, privately negotiated exchange agreements (the “Exchange Agreements”) with certain holders of the Guarantor’s outstanding 5.00% Convertible Senior Notes due 2025.

• Sonendo, Inc. Announces Inducement Grants Under NYSE Listing Rule 303A.08 - September 26, 2023

  9/26/2023

  Sonendo , Inc. (NYSE: SONX), a leading dental technology company and developer of the GentleWave® System, today announced that on September 25, 2023, the Compensation Committee of Sonendo’s Board of Directors granted restricted stock unit awards covering an aggregate of 14,000 shares of its common stock to two new, non-executive employees to induce them to join the company.

• HilleVax Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

  9/25/2023

  HilleVax, Inc. today announced that it has closed its previously announced underwritten public offering of 9,200,000 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase 1,200,000 additional shares, at a price to the public of $12.50 per share.

• XOMA Declares Quarterly Preferred Stock Dividends - September 25, 2023

  9/25/2023

  XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA’s Series A and Series B Cumulative Preferred Stock.

• BridgeBio Pharma Announces $250 Million Private Placement Equity Financing

  9/25/2023

  BridgeBio Pharma, Inc. has entered into a securities purchase agreement with certain existing and new accredited investors to issue and sell an aggregate of 9,167,723 shares of its common stock (Common Stock) at the Friday, September 22, 2023 closing price of $27.27 per share through a private investment in public equity (PIPE) financing.

• Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split

  9/22/2023

  Neoleukin Therapeutics, Inc., today announced that its Board of Directors (“Board”) has approved a reverse stock split of the Company’s outstanding shares of common stock at a ratio of 1-for-5.

• Alzamend Neuro Granted Extension by Nasdaq Panel to Regain Compliance with the Minimum Bid Price Continued Listing Requirement

  9/22/2023

  Alzamend Neuro, Inc. today announced that it received notice from the Nasdaq Hearings Panel (the “ Hearings Panel ”) of The Nasdaq Stock Market LLC (“ Nasdaq ”), which granted Alzamend’s request for continued listing on The Nasdaq Capital Market, subject to Alzamend’s satisfaction of the minimum $1.00 bid price requirement by November 15, 2023.

• 

  5 Life Sciences IPOs in 2023—and the Future Forecast

  9/20/2023

  After a sluggish start to the year, experts expect an uptick in IPO offerings moving into fall, although it’s unlikely 2023 will fully shrug off its slump.

• Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

  9/19/2023

  Eloxx Pharmaceuticals, Inc. today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 380,590 of its shares of common stock (or common stock.

• Sonnet BioTherapeutics Regains Nasdaq Minimum Bid Price Compliance

  9/19/2023

  Sonnet BioTherapeutics Holdings, Inc., announced today that it has received formal notice from the Listing Qualifications staff of The Nasdaq Stock Market indicating that Sonnet has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2).

• RayzeBio, Inc. Announces Closing of Upsized $358 Million Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

  9/19/2023

  RayzeBio, Inc. (Nasdaq: RYZB) today announced the closing of its previously announced upsized $358 million initial public offering (IPO) of 19,869,240 shares of common stock, including the full exercise of the underwriters’ option to purchase up to 2,591,640 additional shares from RayzeBio, at a price to the public of $18.00 per share.

• Virios Therapeutics Announces Termination of At-The-Market Sales Agreement

  9/18/2023

  Virios Therapeutics, Inc. today announced that it provided notice of termination of the Capital on Demand™ Sales Agreement entered into between the Company and JonesTrading Institutional Services LLC on July 14, 2023 (the “Sales Agreement”).

• Titan Pharmaceuticals Announces $9.5 Million Private Placement of Convertible Preferred Stock

  9/18/2023

  Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") announced today that it has entered into a definitive securities purchase agreement (the “Purchase Agreement”) with The Sire Group Ltd.

• 

  Biotech Financing, IPO Tide May Be Turning – Signs of a Potential Recovery?

  9/15/2023

  In the largest biotech Series C financing so far this year, Generate:Biomedicines raised $273 million, while Neumora and RayzeBio announced IPO pricing valued at more than $560 million combined.